Contents

Search

solanezumab

Indications: - none Contraindications: - treatment of Alzheimer's disease Dosage: - 400 mg IV every 4 weeks - up to 1600 mg IV every 4 weeks given in clinical trial [5] Mechanism of action: - immunoglobulin G1 monoclonal antibody that binds to the mid-domain of the beta-amyloid monomer Clinical trials: - solanezumab failed to improve cognitive function in patients with mild to moderate Alzheimer's disease [3] - tested in dominantly inherited Alzheimer's disease with average follow up of 5 years. [4] - does not slow cognitive decline in symptomatic patients or show benefit in Alzheimer markers - does not slow cognitive decline in preclinical Alzheimer's disease [5] - did not result in clearance of brain amyloid plaque [6]

Interactions

drug adverse effects of anti-Alzheimer monoclonal antibody

Related

investigational therapies for treatment of Alzheimer's disease

General

anti-Alzheimer monoclonal antibody

References

  1. Doody RS et al Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. N Engl J Med 2014; 370:311-321. January 23, 2014 PMID: 24450890 http://www.nejm.org/doi/full/10.1056/NEJMoa1312889
  2. Sacks CA, Avorn J, Kesselheim AS The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. N Engl J Med 2017; 376:1706-1708. May 4, 2017 PMID: 28467878 http://www.nejm.org/doi/full/10.1056/NEJMp1701047?query=aging-geriatrics
  3. Honig LS, Vellas B, Woodward M et al Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med 2018; 378:321-330. Jan 25, 2018 PMID: 29365294 http://www.nejm.org/doi/full/10.1056/NEJMoa1705971
  4. George J Investigational Alzheimer's Drug Shows Effects in Inherited Early-Onset Disease MedPage Today June 21,2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93193 - Salloway S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease Nature Medicine (2021) PMID: 34155411 https://www.nature.com/articles/s41591-021-01369-8
  5. Sperling RA et al. Trial of solanezumab in preclinical Alzheimer's disease. N Engl J Med 2023 Jul 17; PMID: 37458272 https://www.nejm.org/doi/10.1056/NEJMoa2305032
  6. Lilly March 8, 2023 Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease. https://investor.lilly.com/node/48566/pdf